Nativi-Nicolau Jose, Ryan John J, Fang James C
Division of Cardiovascular Medicine, Department of Medicine, University of Utah Health Science Center, 50 N Medical Dr, Salt Lake City, UT 84132, USA; Cardiology Section, Veterans Affairs Salt Lake City Health Care System, 500 Foothill Dr, Salt Lake City, UT 84148, USA.
Division of Cardiovascular Medicine, Department of Medicine, University of Utah Health Science Center, 50 N Medical Dr, Salt Lake City, UT 84132, USA.
Heart Fail Clin. 2014 Jul;10(3):525-38. doi: 10.1016/j.hfc.2014.04.007.
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by decreased exercise capacity and fluid retention in the setting of preserved left ventricular systolic function and evidence of abnormal diastolic function. Therapeutic strategies include pharmacologic agents, pacing, baroreflex modification, diet, and exercise. Despite symptomatic and hemodynamic improvements with some therapies, large clinical trials have not demonstrated a clear improvement in clinical outcomes. The current management of patients with HFpEF is directed to symptomatic relief of congestion with diuretics and risk factor modification. In this article, we summarize the available evidence base for potential targets of therapy.
射血分数保留的心力衰竭(HFpEF)是一种临床综合征,其特征为在左心室收缩功能保留及舒张功能异常证据的情况下,运动能力下降和液体潴留。治疗策略包括药物治疗、起搏治疗、压力反射调节、饮食和运动。尽管某些治疗可改善症状和血流动力学,但大型临床试验尚未证明临床结局有明显改善。目前HFpEF患者的管理旨在通过利尿剂缓解充血症状并调整危险因素。在本文中,我们总结了潜在治疗靶点的现有证据基础。